Numis Securities restated their buy rating on shares of Alliance Pharma (LON:APH) in a report released on Friday, MarketBeat.com reports. Numis Securities currently has a GBX 66 ($0.89) price target on the stock, down from their prior price target of GBX 71 ($0.96).
Several other brokerages have also weighed in on APH. FinnCap reissued a buy rating and set a GBX 58 ($0.78) price objective on shares of Alliance Pharma in a report on Thursday, August 24th. Investec initiated coverage on shares of Alliance Pharma in a report on Wednesday, September 13th. They set a buy rating and a GBX 59 ($0.79) price objective for the company. Finally, N+1 Singer reissued a not rated rating on shares of Alliance Pharma in a report on Wednesday, September 13th.
Alliance Pharma (LON:APH) opened at GBX 61.75 ($0.83) on Friday. Alliance Pharma has a fifty-two week low of GBX 41.78 ($0.56) and a fifty-two week high of GBX 62.75 ($0.84).
Alliance Pharma Company Profile
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.
Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with MarketBeat.com's FREE daily email newsletter.